How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research

Area of Science:

• Oncology
• Translational Research
• Patient Advocacy

Background:

• Invasive Lobular Carcinoma (ILC) is the second most common breast cancer subtype, yet research has lagged behind other types.
• ILC exhibits unique biological and therapeutic response characteristics, necessitating subtype-specific investigation.
• Recent advancements highlight ILC's distinct nature, spurring renewed research interest.

Purpose of the Study:

• To explore the opportunity for enhanced collaborative research in lobular breast cancer.
• To leverage recent scientific progress and patient advocacy to drive ILC research forward.
• To improve understanding, diagnosis, and treatment of ILC.

Main Methods:

• Commentary and synthesis of current research trends and advocacy efforts.
• Highlighting the potential of multidisciplinary, multicenter, and international collaborations.
• Emphasizing the integration of patient advocates into the research process.

Main Results:

• ILC's unique biology warrants dedicated research and tailored therapeutic strategies.
• Patient advocacy groups are crucial in connecting patients, researchers, and funding.
• Collaborative research models can accelerate progress in understanding and treating ILC.

Conclusions:

• A concerted, collaborative research approach is essential for advancing ILC care.
• Integrating patient advocates enhances research relevance and patient engagement.
• Targeted therapies and refined standard treatments are achievable through collaborative research for ILC.